 |
 |
|
Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
15 March 1996 | Volume 124 Issue 6 | Pages 573-576
Objective: To determine the effect of fluconazole on rifabutin pharmacokinetics.
Design: An open-label, crossover, phase 1 trial.
Setting: Outpatient clinical research center at a university medical center in Washington, D.C.
Patients: 12 persons with human immunodeficiency virus (HIV) infection whose CD4 lymphocyte counts were between 200 and 500 cells/mm3 and who were receiving maintenance therapy with zidovudine.
Intervention: Fluconazole, 200 mg/d for 2 weeks; then a combination of fluconazole, 200 mg/d, and rifabutin, 300 mg/d, for 2 weeks; and then rifabutin, 300 mg/d, for the final 2 weeks of the study.
Measurements: Blood and urine samples were obtained at regular intervals for 24 hours at the end of each 2-week dosing period to ascertain concentrations of fluconazole and rifabutin and the 25-desacetyl metabolite of rifabutin, LM565.
Results: Fluconazole significantly increased the plasma concentrations of both rifabutin and LM565. Mean increases in the area under the plasma concentration curve compared with the time curve over a 24-hour dosing interval were 82% (5442 ± 2404 ng · h/mL compared with 3025 ± 1117 ng · h/mL; P
Conclusions: Fluconazole significantly increases the systemic exposure of both rifabutin and LM565. This pharmacokinetic interaction offers a mechanism that may explain the changes reported in both the efficacy and toxicity of rifabutin with concomitant fluconazole therapy.
Author and Article Information
From the Georgetown University Medical Center, Washington, D.C.; Food and Drug Administration, Rockville, Maryland; and Pharmacia, Inc., Columbus, Ohio.
BRIEF COMMUNICATION
Increased Plasma Rifabutin Levels with Concomitant Fluconazole Therapy in HIV-Infected Patients
0.05) for rifabutin and 216% (959 ± 529 ng · h/mL compared with 244 ± 141 ng · h/mL; P 0.05) for LM565.
Acknowledgments: The authors thank Catherine O'Leary, RN, Mr. David James, and Mr. David Colborn for technical support and Darrell Abernethy, MD, PhD, Jerry Collins, PhD, and Charles W. Flexner, MD, for manuscript review.
Grant Support: In part by Pharmacia, Inc., Columbus, Ohio.
Requests for Reprints: Carol Braun Trapnell, MD, Food and Drug Administration, Center for Drug Evaluation and Research, 5600 Fishers Lane, HFD-900, Room 13B-16, Rockville, MD 20857.
Current Author Addresses: Dr. Trapnell: Food and Drug Administration, Center for Drug Evaluation and Research, 5600 Fishers Lane, HFD-900, Room 13B-16, Rockville, MD 20857.
This article has been cited by other articles:
|
|
 |
|
  H. Zhou Population-based assessments of clinical drug-drug interactions: qualitative indices or quantitative measures? J. Clin. Pharmacol., November 1, 2006; 46(11): 1268 - 1289. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Galetin, K. Ito, D. Hallifax, and J. B. Houston CYP3A4 Substrate Selection and Substitution in the Prediction of Potential Drug-Drug Interactions J. Pharmacol. Exp. Ther., July 1, 2005; 314(1): 180 - 190. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. C. Piscitelli and K. D. Gallicano Interactions among Drugs for HIV and Opportunistic Infections N. Engl. J. Med., March 29, 2001; 344(13): 984 - 996. [Full Text] [PDF]
|
|
|
|
 |
|
 R. E. Polk, D. F. Brophy, D. S. Israel, R. Patron, B. M. Sadler, G. E. Chittick, W. T. Symonds, Y. Lou, D. Kristoff, and D. S. Stein Pharmacokinetic Interaction between Amprenavir and Rifabutin or Rifampin in Healthy Males Antimicrob. Agents Chemother., February 1, 2001; 45(2): 502 - 508. [Abstract] [Full Text]
|
|
|
|
|
|
M. K. Jordan, M. A. Polis, G. Kelly, P. K. Narang, H. Masur, and S. C. Piscitelli Effects of Fluconazole and Clarithromycin on Rifabutin and 25-O-Desacetylrifabutin Pharmacokinetics Antimicrob. Agents Chemother., August 1, 2000; 44(8): 2170 - 2172. [Abstract] [Full Text]
|
|
|
|
 |
|
 S. M. Yule, D. Walker, M. Cole, L. McSorley, S. Cholerton, A. K. Daly, A.D.J. Pearson, and A. V. Boddy The Effect of Fluconazole on Cyclophosphamide Metabolism in Children Drug Metab. Dispos., March 1, 1999; 27(3): 417 - 421. [Abstract] [Full Text]
|
|
|
|
|
|
G. Gatti, P. Papa, D. Torre, M. Andreoni, A. Poggio, M. Bassetti, and P. Marone Population Pharmacokinetics of Rifabutin in Human Immunodeficiency Virus-Infected Patients Antimicrob. Agents Chemother., August 1, 1998; 42(8): 2017 - 2023. [Abstract] [Full Text]
|
|
|
|
|
|
C. B. Trapnell, R. W. Klecker, C. Jamis-Dow, and J. M. Collins Glucuronidation of 3'-Azido-3'-Deoxythymidine (Zidovudine) by Human Liver Microsomes: Relevance to Clinical Pharmacokinetic Interactions with Atovaquone, Fluconazole, Methadone, and Valproic Acid Antimicrob. Agents Chemother., July 1, 1998; 42(7): 1592 - 1596. [Abstract] [Full Text]
|
|
|
|
 |
|
 R. RIDZON, C. G. WHITNEY, M. T. MCKENNA, J. P. TAYLOR, S. H. ASHKAR, A. T. NITTA, S. M. HARVEY, S. VALWAY, C. WOODLEY, R. COOKSEY, et al. Risk Factors for Rifampin Mono-resistant Tuberculosis Am. J. Respir. Crit. Care Med., June 1, 1998; 157(6): 1881 - 1884. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Hafner, J. Bethel, M. Power, B. Landry, M. Banach, L. Mole, H. C. Standiford, S. Follansbee, P. Kumar, R. Raasch, et al. Tolerance and Pharmacokinetic Interactions of Rifabutin and Clarithromycin in Human Immunodeficiency Virus-Infected Volunteers Antimicrob. Agents Chemother., March 1, 1998; 42(3): 631 - 639. [Abstract] [Full Text]
|
|
|
|
|
|
D. V. Havlir, M. P. Dube, F. R. Sattler, D. N. Forthal, C. A. Kemper, M. W. Dunne, D. M. Parenti, J. P. Lavelle, A. C. White, M. D. Witt, et al. Prophylaxis against Disseminated Mycobacterium avium Complex with Weekly Azithromycin, Daily Rifabutin, or Both N. Engl. J. Med., August 8, 1996; 335(6): 392 - 398. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Fluconazole/Rifabutin Interaction AIDS Clinical Care, May 1, 1996; 1996(501): 3 - 3. [Full Text]
|
|
Article
